StreetInsider.com News Articles

Form 3 Autonomix Medical, Inc. For: Sep 14 Filed by: Kalter Sandra C

Tue, 13 Oct 2026 14:05:00 -0400

si-local-file:///var/storage/secattach/20261013/27180530.html

Autonomix Medical receives Canadian patent for catheter-based nerve therapy

Fri, 02 Oct 2026 08:06:15 -0400

Autonomix Medical, Inc. (NASDAQ: AMIX) announced that the Canadian Intellectual Property Office has issued Canadian Patent No. 3,183,802, titled "Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within and/or Through a Lumen Wall."

The patent covers catheter-based transvascular tools and systems designed to operate from within a bodily lumen, where deployable probes penetrate into or through a lumen wall to access tissue and nerves located outside the vessel. It includes multi-site electrophysiological sensing, closed-loop control capabilities for real-time adjustment of therapeutic energy delivery, and methods for assessing procedural completion based on electrophysiological signal processing.

Corresponding patents covering related inventions have

Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation

Fri, 02 Oct 2026 08:05:00 -0400

Patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall

Patent reinforces Autonomix’s transvascular intervention platform across multiple nerve-targeted therapies

THE WOODLANDS, TX, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the Canadian Intellectual Property Office (CIPO) has issued Canadian Patent No. 3,183,802, titled, "Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within and/or Through a Lumen Wall." The Company’s

Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation

Fri, 02 Oct 2026 08:05:00 -0400

Patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall

Patent reinforces Autonomix’s transvascular intervention platform across multiple nerve-targeted therapies

Autonomix gets FDA backing for 510(k) path for sensing platform

Wed, 30 Sep 2026 08:30:23 -0400

Autonomix Medical, Inc. (NASDAQ: AMIX) announced it has completed a pre-submission meeting with the U.S. Food and Drug Administration regarding its standalone transvascular sensing platform, receiving feedback that supports a Class II regulatory pathway toward potential U.S. clearance.

According to the company, the FDA's guidance indicates that a substantial equivalence strategy — referencing an already-cleared device — may be used to support a 510(k) submission for the sensing platform. The company said it is targeting potential U.S. clearance in approximately 15 months, contingent on completing development and validation activities and FDA review.

The sensing platform is designed to detect and differentiate biological

Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance

Wed, 30 Sep 2026 08:30:00 -0400

FDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning the Company for potential initial U.S. clearance of its standalone sensing platform in approximately 15 months

THE WOODLANDS, TX, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of a pre-submission meeting with the U.S. Food and Drug Administration (FDA) regarding the Company’s recently announced standalone transvascular sensing platform, which is designed to detect and differentiate

Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance

Wed, 30 Sep 2026 08:30:00 -0400

Autonomix Medical receives European patent for neural activity system

Thu, 24 Sep 2026 08:30:25 -0400

Autonomix Medical, Inc. (NASDAQ: AMIX) announced the grant of European Patent No. EP 4 233 700 B1, titled "Systems for Assessing Neural Activity in an Eye," adding to the company's international intellectual property portfolio.

The patent covers technologies designed to assess autonomic nervous system activity by monitoring and analyzing neural activity within the eye. It includes systems and methods for evaluating physiologic responses through ocular measurements intended to support patient assessment, treatment guidance, and procedural feedback across autonomic nervous system disorders and neuromodulation applications.

"This European patent represents another important step in expanding our global intellectual property footprint," said Brad Hauser, Chief

Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform

Thu, 24 Sep 2026 08:30:00 -0400

European patent strengthens protection for proprietary autonomic nervous system assessment technologies, further expanding Company's international patent portfolio

THE WOODLANDS, TX, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the grant of European Patent No. EP 4 233 700 B1, titled "Systems for Assessing Neural Activity in an Eye." The newly issued patent further expands the Company's international intellectual property portfolio and strengthens protection for technologies supporting autonomic nervous system assessment and precision neuromodulation across Europe.

Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform

Thu, 24 Sep 2026 08:30:00 -0400

European patent strengthens protection for proprietary autonomic nervous system assessment technologies, further expanding Company's international patent portfolio

Form 4 Autonomix Medical, Inc. For: Sep 03 Filed by: Smith Trent N.

Mon, 21 Sep 2026 08:14:00 -0400

si-local-file:///var/storage/secattach/20260921/27083276.html

Form 424B3 Autonomix Medical, Inc.

Wed, 16 Sep 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260916/27071067.html

Form 8-K Autonomix Medical, Inc. For: Sep 14

Wed, 16 Sep 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260916/27067939.html

Autonomix Medical adds ex-Medtronic regulatory counsel to its board

Wed, 16 Sep 2026 08:30:18 -0400

Autonomix Medical, Inc. (NASDAQ: AMIX) has appointed Sandra Cohen Kalter, former Vice President and Chief Regulatory Counsel of Medtronic plc, to its board of directors, according to a press release from the medical device company.

Kalter spent 20 years at Medtronic in senior legal and regulatory leadership roles, where she advised business units on FDA strategy, clinical and legal regulatory matters, and product development. During her tenure, she oversaw due diligence and integration activities for more than 27 acquisitions. Her work at Medtronic included regulatory and strategic involvement with the Symplicity Spyral Renal Denervation system, Evolut TAVR platform, Micra Transcatheter Pacing

Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors

Wed, 16 Sep 2026 08:30:00 -0400

Appointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervation and other category-defining technologies

THE WOODLANDS, TX, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the appointment of Sandra Cohen Kalter, former Vice President and Chief Regulatory Counsel of Medtronic plc (Medtronic) as a Board Member for Autonomix.

Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors

Wed, 16 Sep 2026 08:30:00 -0400

Form EFFECT Autonomix Medical, Inc.

Wed, 16 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260916/27067033.html

Form DEFA14A Autonomix Medical, Inc.

Mon, 14 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260914/27059267.html

Form DEF 14A Autonomix Medical, Inc. For: Oct 29

Mon, 14 Sep 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260914/27059187.html

Form 424B5 Autonomix Medical, Inc.

Fri, 11 Sep 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260911/27053562.html

Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026

Tue, 01 Sep 2026 08:30:00 -0400

Abstracts highlight potential of Autonomix’s transvascular technology across pain management and nervous system mapping

THE WOODLANDS, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two scientific abstracts have been accepted for poster presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress, taking place September 5-9, 2026, in Copenhagen, Denmark.

The accepted abstracts, both presented by Dr. Robert Schwartz of Autonomix, highlight the potential of the Company’s

Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026

Tue, 01 Sep 2026 08:30:00 -0400

Abstracts highlight potential of Autonomix’s transvascular technology across pain management and nervous system mapping

The accepted abstracts, both presented by Dr. Robert Schwartz of Autonomix, highlight the potential of the Company’s

Form 8-K Autonomix Medical, Inc. For: Aug 24

Wed, 26 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260826/26982714.html

Form 8-K Autonomix Medical, Inc. For: Aug 24

Wed, 26 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260826/26982714.html

Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery

Wed, 26 Aug 2026 08:30:00 -0400

New patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pain

THE WOODLANDS, TX, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the issuance of U.S. Patent No. 12,714,780 by the United States Patent and Trademark Office (USPTO), titled “Systems and Methods for Regulating Organ and/or Tumor Growth Rates, Function, and/or Development” on August 25, 2026.

The newly issued patent